This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Legal Questions Still Dogging Wyeth

"Wyeth must fight a two-front battle," says Elizabeth Chamblee Burch, assistant professor of law at the Florida State University College of Law. "On the one hand, it will worry about a never-ending litigation stream and have difficulty quantifying the risks. On the other hand, it will try to protect the Premarin and Prempro names."

In the case of Lilly's schizophrenia drug Zyprexa, which also remains on the market, the drug's maker settled with most of the 31,300 claimants, paying $1.2 billion, and says it will fight claims by other plaintiffs, according to a recent filing with the Securities and Exchange Commission.

Hormone-therapy plaintiffs could have a tougher time winning based on alleged side effects. Zyprexa plaintiffs claimed the drug caused or contributed to higher blood sugar or diabetes. Diet-drug plaintiffs alleged rare side effects such as heart-valve damage or dangerously high blood pressure in arteries of the lungs.

In the hormone-therapy cases, claims involve illnesses that Wyeth's attorneys can try to attribute to many causes. "A longer latency period [for cancer] makes proving causation more difficult since there is an opportunity for additional intervening factors," says Burch.

"There are so many different causes for breast cancer," says Thomas Metzloff, professor of law at the Duke University School of Law. "The legal system wants something where causation is clear."

The most successful plaintiffs' lawsuits, he says, involve "a signature illness" such as the diseases linked to Wyeth's diet drugs or the lung-cancer mesothelioma, which has been tied to asbestos exposure.
2 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
MRK $55.72 -1.00%
AAPL $94.84 -3.00%
FB $116.78 7.20%
GOOG $691.17 -2.10%
TSLA $247.62 -1.50%


Chart of I:DJI
DOW 17,830.76 -210.79 -1.17%
S&P 500 2,074.51 -20.64 -0.99%
NASDAQ 4,805.6670 -57.4740 -1.18%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs